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Abstract
Background: Biomarkers of the immune system are currently not used as prognostic factors in breast cancer. We analyzed
the association of the B cell/plasma cell marker immunoglobulin kappa C (IGKC) and survival of untreated node-negative
breast cancer patients.
Material and Methods: IGKC expression was evaluated by immunostaining in a cohort of 335 node-negative breast cancer
patients with a median follow-up of 152 months. The prognostic significance of IGKC for disease-free survival (DFS) and
breast cancer-specific overall survival (OS) was evaluated with Kaplan-Meier survival analysis as well as univariate and
multivariate Cox analysis adjusted for age at diagnosis, pT stage, histological grade, estrogen receptor (ER) status,
progesterone receptor (PR) status, Ki-67 and human epidermal growth factor receptor 2 (HER-2) status.
Results: 160 patients (47.7%) showed strong expression of IGKC. Univariate analysis showed that IGKC was significantly
associated with DFS (P = 0.017, hazard ratio [HR] = 0.570, 95% confidence interval [CI] = 0.360–0.903) and OS (P = 0.011,
HR = 0.438, 95% CI = 0.233–0.822) in the entire cohort. The significance of IGKC was especially strong in ER negative and in
luminal B carcinomas. In multivariate analysis IGKC retained its significance independent of established clinical factors for
DFS (P = 0.004, HR = 0.504, 95% CI = 0.315–0.804) as well as for OS (P = 0.002, HR= 0.371, 95% CI = 0.196–0.705).
Conclusion: Expression of IGKC has an independent protective impact on DFS and OS in node-negative breast cancer.
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Introduction
For many years researchers have tried to characterize prognos-
tic factors, but have only made limited progress [1]. Predicting the
prognosis of patients still relies largely on traditional prognostic
factors such as age, pT stage and histological grade. Gene-based
testing like Oncotype DX, Endopredict or Mamma Print is
increasingly used to determine prognosis [2–4]. However, these
gene-expression arrays rely largely on proliferation and estrogen
receptor (ER) status. It is increasingly recognized that the immune
system, especially adaptive immune cells, has a large influence on
the prognosis of breast cancer [5,6]. The impact of adaptive
cellular immune response, represented by CD8+ T cells, was
studied most intensely. Many studies found that CD8+ T cells
were associated with good prognosis [7–9]. Though the favourable
impact of CD8+ T cells has been substantiated by these studies,
the role of the humoral system, represented by B cells/plasma cells
was acknowledged only recently [10–13].
In this regard, a recent study reported that 55% out of the 1470
breast cancers were infiltrated by B cells [11]. Wang et al. showed
that an immune response against tumour-derived antigens led to
the maturation and differentiation of B cells and that immuno-
globulin (Ig) G was the dominant isotype in invasive breast
tumours [14]. Accordingly, several studies showed that B cells
were significantly associated with better prognosis [10–12].
Despite these findings, some experimental studies pointed to an
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adverse role of B cells suggesting that B cells may under certain
conditions also stimulate progression of breast cancer [15–18].
Utilizing microarray-based gene-expression analysis, we could
show that a stronger expression of a B cell metagene was
associated with improved survival in node-negative breast cancer
[10]. Building on these results, we described that immunoglobulin
Kappa C (IGKC), a single gene of this B cell metagene, was found
to be a representative marker and showed a favourable metastasis-
free survival (MFS) in breast cancer both at the ribonucleic acid
(RNA) and at the protein level [12]. Based on these encouraging
findings, we examined in the present study the impact of
immunohistochemically detected IGKC for disease-free survival
(DFS) and breast cancer-specific overall survival (OS) in node-
negative breast cancer patients who did not receive systemic
therapy in the adjuvant setting. We also analysed the prognostic
impact of IGKC in subgroups according to estrogen receptor
expression as well as in luminal A and luminal B carcinomas.
Methods
Study Patients
Our initial study cohort included 410 consecutive lymph
node-negative breast cancer patients not treated in the adjuvant
setting. The tumor size was pT1 to pT3 and there was adequate
follow-up information of patients who were treated at the
Department of Obstetrics and Gynaecology of Johannes
Gutenberg University Mainz between the years 1985 and
2001. Of these 410 patients, paraffin blocks with tumour tissue
for IGKC immunohistochemistry (IHC) were available of 335
individuals who were analysed in this study. All these patients
were treated by surgical tumour resection and did not receive
any systemic adjuvant therapy. pT stage was collected from the
pathology report of the Gynaecological Pathology Division.
From the breast cancer database [19], results of age at
diagnosis, histological grade, estrogen receptor (ER) status,
progesterone receptor (PR) as well as Ki-67 and human
epidermal growth factor receptor 2 (HER-2) status were
obtained. Briefly, serial sections of formalin-fixed and paraffin-
embedded tumor tissues were stained with monoclonal ER
antibodies (clone 1D5, Dako, Glostrup, Denmark), monoclonal
progesterone receptor (PR) antibodies (clone PgR 636, Dako,
Glostrup, Denmark), monoclonal Ki-67 antibodies (clone MIB-
1, Dako, Glostrup, Denmark) as well as polyclonal HER-2
antibodies (A0485, Dako, Glostrup, Denmark). HER-2 was
scored from 0 to 3+ according to the well-published manufac-
turer’s instructions. HER-2 3+ tumors were considered HER-2
positive. All HER-2 2+ cases were confirmed by Fluorescence
in-situ hybridization (FISH) using a dual-color probe (DakoCy-
tomation) containing a spectrum orange-labeled HER-2 gene
(17q11.2-q12) probe and a spectrum green-labeled centromere
control for chromosome 17 (17p11.1-q11.1). HER-2 tumors
with 2+ HER-2 amplification were finally considered HER-2
positive. ER and PR expression was analysed as percentage of
all tumor cells and any nuclear expression .0 was considered
positive. Ki67 expression of more than 20% was considered as
high expression and a percentage #20% was defined as low
expression [20]. Luminal A and luminal B type carcinomas
were defined according to Goldhirsch et al. [21]. Briefly, ER
and/or PR positive carcinomas were defined as luminal A if
they were both HER2 negative and well or moderately
differentiated. Conversely, ER and/or PR positive carcinomas
were classified as luminal B if they were either HER2 positive
or poorly differentiated. Among 410 breast cancer patients, 224
(55%) patients were treated with breast conserving surgery
Figure 1. Representative examples of IGKC immunostaining in a positive control and breast cancer. (A) Normal human tonsil tissue,
strong IGKC positive infiltrate was mainly distributed in the parafollicular area (original magnification: 100-fold; inset: 400-fold). (B) Strong IGKC
positive infiltrate in invasive breast cancer (IGKC positive infiltrate score: 3+) (original magnification: 100-fold; inset: 400-fold). (C) Strong IGKC positive
infiltrate in medullary breast cancer (IGKC positive infiltrate score: 3+) (original magnification: 200-fold; inset: 400-fold). (D) Moderate IGKC positive
infiltrate (IGKC positive infiltrate score: 2+) (original magnification: 400-fold). (E) Weak IGKC positive infiltrate (IGKC positive infiltrate score: 1+)
(original magnification: 400-fold). (F) IGKC negative breast cancer (IGKC positive infiltrate score: 0) (original magnification: 400-fold).
doi:10.1371/journal.pone.0044741.g001
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followed by irradiation and 185 (45%) with modified radical
mastectomy. We only included node-negative breast cancer
patients with pT1–3 tumours without any evidence of metastatic
disease at the time of surgery. The median age at diagnosis of
the patients was 60 years (range 33 to 91 years). We
documented death from cancer or from other reasons unrelated
to breast cancer and recurrence of disease, which include
metastasis, local relapse and secondary tumours. The mean
follow-up time was 152 months. 45 (13.4%) patients died from
breast cancer, 41 (12.3%) patients died from other diseases
unrelated to breast cancer, 6 (1.8%) patients died from
unknown causes, 243 (72.5%) patients were alive and 78
(23.3%) patients suffered from recurrent disease. The patients
dying from other reasons were censored from their survival
statistics analysis at their date of death. The study was approved
by the ethical review board of the medical association of
Rhineland-Palatinate. The manuscript was prepared in agree-
ment with the reporting recommendations for tumor marker
reporting studies [22].
Ethics Statement
The study was approved by the ethical review board of the
medical association of Rhineland-Palatinate. Informed consent has
been obtained and all clinical investigation has been conducted
according to the principles expressed in the Declaration of
Helsinki.
Immunohistochemistry
Immunostaining was done on 4 mm thick sections according to
standard procedures as previously described [14]. Briefly, serial
sections of formalin-fixed and paraffin-embedded tumour tissue
were subsequently deparaffinized using graded alcohol and
xylene. Antigen retrieval reactions were performed in a steamer
in citrate buffer of pH10 for 30 minutes. 3% H2O2 solution was
applied to block endogenous peroxidase at room temperature for
5 minutes. Monoclonal IGKC antibodies (Clone KP-53; Santa
Cruz Biotechnology Company, Santa Cruz, California, USA) in
a dilution of 1:100 was used to incubate with the tissue sections
for 30 minutes at room temperature in a humidified chamber,
followed by polymeric biotin–free visualization system (Envi-
sionTM, DAKO Diagnostic Company, Hamburg, Germany)
reaction for 30 minutes at room temperature. Then the sections
were incubated with 3, 3-diaminobenzidine (DAB) (EnvisionTM,
DAKO Diagnostic Company, Hamburg, Germany) in a dilution
of 1:50 with substrate buffer for 5 minutes at room temperature
and counterstained with Mayer’s haematoxylin solution for 5
minutes. All slides were mounted and then were evaluated under
a Leica light microscope (Leica Microsystem Vertrieb Company,
Wetzler, Germany) by two of the authors trained in histological
and immunohistochemical diagnostics, unaware of the clinical
outcome. All series included appropriate positive (tonsil) and
negative (hepatocytes) controls, and all controls gave adequate
results.
Evaluation of Immunostaining
Evaluation was performed as previously described [12]. Since
only the total number of B cells, irrespective of location, was found
to be associated with prognosis [11], a semi-quantitative scoring
method similar to that used by other studies [23,24] was employed
to evaluate the intensity of IGKC positive infiltrate: 0, no IGKC
positive infiltrate; 1+, weak IGKC positive infiltrate; 2+, moderate
IGKC positive infiltrate; 3+, strong IGKC positive infiltrate. To
dichotomize the patients, cases with IGKC score 0 and 1+ were
considered as having low IGKC expression and cases with 2+ and
3+ as high IGKC expression, respectively. Additionally, we
examined as IGKC status the differentiation between 0 (unequiv-
ocally negative) and positive (any staining, not regarding the
extent). In case of disagreement of the results of two independent
Table 1. Clinicopathological characteristics of all patients
(n = 335).
Characteristics Number %
Age at diagnosis
,50 years 84 25.1
$50 years 251 74.9
pT stage
pT1 222 66.3
pT2 110 32.8
pT3 3 0.9
Histological grade
G I 87 26.0
G II 183 54.6
G III 65 19.4
Estrogen receptor status
Negative 64 19.1
Positive 271 80.9
Progesterone receptor status
Negative 92 27.5
Positive 243 72.5
HER-2 status
Negative 290 86.6
Positive 45 13.4
Ki-67 expression
Low 235 70.1
High 87 26.0
Missing 13 3.9
IGKC positive infiltrate score
0 79 23.6
1+ 96 28.7
2+ 43 12.8
3+ 117 34.9
IGKC expression
Low 175 52.3
High 160 47.7
IGKC status
Negative 79 23.6
Positive 256 76.4
Death 92 27.5
Due to cancer 45 13.4
Unrelated to cancer 41 12.3
Unknown causes 6 1.8
Surviving 243 72.5
Relapse
Yes 78 23.3
No 257 76.7
HER-2 human epidermal growth factor receptor 2.
doi:10.1371/journal.pone.0044741.t001
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examiners the slides were re-examined and discussed at the
microscope until a consensus was reached.
Statistical Analysis
Survival rates were calculated according to the Kaplan-Meier
method. Breast cancer-specific DFS was calculated from the
diagnosis date to the date of recurrence including local relapse,
distant metastasis, detection of the contra lateral breast cancer
and death from cancer. Breast cancer-specific OS was
computed from the date of diagnosis to the date of death from
breast cancer. Patients who died of an unrelated cause were
censored at the date of death. Survival was compared with the
Log-rank test. Univariate and multivariate Cox analysis with
proportional hazard regression model were employed to assess
the impact of IGKC and other prognostic factors. Multivariate
Cox survival analyses were done with inclusion. Dichotomiza-
tion was done as follows: IGKC expression in low and high, age
at diagnosis in ,50 years and $50 years, pT stage in pT1
(#2 cm) versus pT2 and pT3 (.2 cm), histological grade in G I
and G II versus G III, ER status in negative and positive, PR
status in negative and positive, HER-2 status in negative and
positive, and Ki-67 expression in low and high. IGKC
expression in the whole cohort as well as in ER positive, ER
negative, luminal A and luminal B were assessed and Kaplan-
Meier calculation, univariate and multivariate Cox analysis of
IGKC expression for DFS and OS were done. Correlations
between IGKC expression, age at diagnosis, pT stage,
histological grade, ER status, PR as well as HER-2 status and
Ki-67 expression were analyzed using the Chi-Square test
(likelihood quotient). All P values were two sided. Since no
Figure 2. Association of IGKC expression with prognosis in the entire cohort (n =335). Kaplan Meier survival analysis illustrated that high
IGKC expression was significantly associated with longer DFS (Log-rank test: P = 0.015; Fig. 2A) and longer OS (Log-rank test: P = 0.009; Fig. 2B). A
comparable prognostic influence was seen when IGKC status was used for DFS (Log-rank test: P = 0.006; Fig. 2C) and OS (Log-rank test: P = 0.009; Fig.
2D), respectively.
doi:10.1371/journal.pone.0044741.g002
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correction for multiple testing was done, all results were
interpreted as explorative. All statistical analyses were done
using the Statistical Package for the Social Science (SPSS) (SPSS
Inc, version 15.0, Chicago, IL, USA).
Results
Results of Immunohistochemistry
Established clinicopathological variables were assessed, includ-
ing age at diagnosis, pT stage, histological grade, ER, PR as
well as HER-2 status and Ki-67 expression (Table 1). IGKC
expression was determined by immunohistochemistry (IHC)
(Fig. 1). IGKC was found mainly in the tumour stroma. Using
the IGKC scoring method [14], 79 (23.6%) patients were scored
0, 96 (28.7%) patients were scored 1+, 43 (12.8%) patients were
scored 2+ and 117 (34.9%) patients were scored 3+. In order to
obtain a comparable size of the groups, we combined score 0
and 1+ as well as 2+ and 3+, respectively. Accordingly, 175
(52.3%) patients were considered to have low IGKC expression
and 160 (47.7%) patients to have high IGKC expression,
respectively. For comparison, we also showed Kaplan Meier
plots for IGKC status negative (n = 79; 23.6%) vs. positive
(n = 256; 76.4%) in the entire cohort of patients. Only low and
high IGKC expression was used for further analysis of the
prognostic relevance of IGKC.
IGKC has Protective Impact on Prognosis of Node-
negative Breast Cancer Patients
In the total patient series, IGKC expression (P = 0.017,
HR=0.570, 95% CI= 0.360–0.903; Table 2A) showed a statis-
tically significant association with DFS in univariate Cox analysis.
In addition, histological grade (P,0.001, HR=3.404, 95%
CI= 2.155–5.377; Table 2A), HER-2 status (P = 0.002,
HR=2.282, 95% CI= 1.360–3.827; Table 2A) and Ki-67
expression (P= 0.001, HR=2.193, 95% CI=1.385–3.472;
Table 2A) also had statistically significant associations with DFS.
Kaplan-Meier plots illustrate a protective impact of IGKC
expression on DFS (Log-rank test: P = 0.015; Fig. 2A). A similar
effect was seen when IGKC status was used (Log-rank test:
P = 0.006; Fig. 2C) In the multivariate Cox regression model
including age at diagnosis, pT stage, histological grade, ER as well
as PR and HER-2 status, high IGKC expression was indepen-
dently associated with improved DFS (P= 0.004, HR=0.504,
95% CI= 0.315–0.805; Table 2B). Besides IGKC expression,
histological grade (P,0.001, HR=3.617, 95% CI= 2.197–5.954;
Table 2B) and HER-2 status (P = 0.011, HR=2.015, 95%
CI= 1.176–3.454; Table 2B) were also independently associated
with DFS.
Table 2. Cox regression analysis of IGKC expression for
disease-free survival (DFS) in the entire cohort (n = 335).
Clinicopathological Characteristics HR 95% CI P
A. Univariate Cox analysis
IGKC expression (low vs. high) 0.570 0.360–0.903 0.017
Age (,50 years vs. $50 years) 1.290 0.764–2.176 0.341
pT stage (#2 cm vs. .2 cm) 1.354 0.862–2.127 0.188
Histological grade (G I and II vs. G III) 3.404 2.155–5.377 ,0.001
ER status (negative vs. positive) 0.802 0.472–1.360 0.412
PR status (negative vs. positive) 0.759 0.473–1.216 0.251
HER-2 status (negative vs. positive) 2.282 1.360–3.827 0.002
Ki-67 expression a (low vs. high) 2.193 1.385–3.472 0.001
B. Multivariate Cox analysis
IGKC expression (low vs. high) 0.504 0.315–0.805 0.004
Age (,50 years vs. $50 years) 1.206 0.704–2.065 0.495
pT stage (#2 cm vs. .2 cm) 1.430 0.901–2.269 0.129
Histological grade (G I and II vs. G III) 3.617 2.197–5.954 ,0.001
ER status (negative vs. positive) 1.394 0.660–2.941 0.384
PR status (negative vs. positive) 0.963 0.501–1.849 0.909
HER-2 status (negative vs. positive) 2.015 1.176–3.454 0.011
ER Estrogen receptor; PR Progesterone receptor; HER-2 human epidermal
growth factor receptor 2; HR hazard ratio; 95%-CI 95%-confidence interval.
aThe total number of available cases for Ki-67 expression in univariate Cox
regression analysis is 322.
doi:10.1371/journal.pone.0044741.t002
Table 3. Cox regression analysis of IGKC expression for
overall survival (OS) in the entire cohort (n = 335).
Clinicopathological Characteristics HR 95% CI P
A. Univariate Cox analysis
IGKC expression (low vs. high) 0.438 0.233–0.824 0.011
Age (,50 years vs. $50 years) 1.140 0.584–2.223 0.702
pT stage (#2 cm vs. .2 cm) 1.744 0.971–3.134 0.063
Histological grade (G I and II vs. G III) 4.630 2.577–8.321 ,0.001
ER status (negative vs. positive) 0.753 0.381–1.488 0.415
PR status (negative vs. positive) 0.849 0.452–1.597 0.613
HER-2 status (negative vs. positive) 2.520 1.301–4.881 0.006
Ki-67 expression a (low vs. high) 2.701 1.502–4.858 0.001
B. Multivariate Cox analysis
IGKC expression (low vs. high) 0.375 0.197–0.713 0.003
Age (,50 years vs. $50 years) 1.097 0.551–2.182 0.793
pT stage (#2 cm vs. .2 cm) 1.848 1.012–3.374 0.046
Histological grade (G I and II vs. G III) 5.206 2.766–9.801 ,0.001
ER status (negative vs. positive) 1.202 0.413–3.504 0.736
PR status (negative vs. positive) 1.349 0.505–3.606 0.551
HER-2 status (negative vs. positive) 2.333 1.166–4.668 0.017
ER Estrogen receptor; PR Progesterone receptor; HER-2 human epidermal
growth factor receptor 2; HR hazard ratio; 95%-CI 95%-confidence interval.
aThe total number of available cases for Ki-67 expression in univariate Cox
regression analysis is 322.
doi:10.1371/journal.pone.0044741.t003
Table 4. Bivariate Cox analysis of IGKC expression with Ki-67
expression for disease-free survival (DFS) (A) and overall
survival (OS) (B) (n = 322).
Clinicopathological Characteristics HR 95% CI P
A. Disease free survival (DFS)
IGKC expression (low vs. high) 0.555 0.346–0.889 0.014
Ki-67 expression (low vs. high) 2.131 1.345–3.376 0.001
B. Overall survival (OS)
IGKC expression (low vs. high) 0.466 0.248–0.877 0.018
Ki-67 expression (low vs. high) 2.626 1.460–4.725 0.001
HR hazard ratio; 95%-CI 95%-confidence interval.
doi:10.1371/journal.pone.0044741.t004
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Similarly as for DFS, also OS showed associations with IGKC
expression (P= 0.011, HR=0.438, 95% CI= 0.233–0.824;
Table 3A), histological grade (P,0.001, HR=4.630, 95%
CI= 2.577–8.321; Table 3A), HER-2 status (P = 0.006,
HR=2.520, 95% CI= 1.301–4.881; Table 3A) and Ki-67
expression (P= 0.001, HR=2.701, 95% CI= 1.502–4.858;
Table 3A) in the univariate Cox analysis. Furthermore, Kaplan
Meier survival analysis visualized a strong difference in OS time
between patients with low and high IGKC expression (Log-rank
test: P = 0.009; Fig. 2B). A prognostic significance of similar
magnitude was seen when IGKC status was used (Log-rank test:
P = 0.009; Fig. 2D). Performing multivariate Cox analysis adjusted
for age at diagnosis, pT stage, histological grade, ER as well as PR
and HER-2 status, high IGKC expression was associated with
better OS independent of other prognostic factors (P = 0.003,
HR=0.375, 95% CI= 0.197–0.713; Table 3B). In this multivar-
iate Cox regression model, also pT stage (P= 0.046, HR=1.848,
95% CI= 1.012–3.374; Table 3B), histological grade (P,0.001,
HR=5.206, 95% CI= 2.766–9.801; Table 3B) and HER-2 status
(P = 0.017, HR=2.333, 95% CI=1.166–4.668; Table 3B) were
associated with OS.
Conducting bivariate Cox analysis, IGKC expression had
statistically significant associations with DFS (P= 0.014,
HR=0.555, 95% CI= 0.346–0.889; Table 4A) as well as OS
(P= 0.018, HR=0.466, 95%CI= 0.248–0.877; Table 4B) inde-
pendent of Ki-67 expression.
Prognostic Significance of IGKC in Subgroups According
to ER and Luminal Status
In ER negative carcinomas (n = 64), both DFS and OS were
significantly associated with IGKC expression. Kaplan Meier plots
Figure 3. In ER negative carcinomas (n=64), high IGKC expression had a significant association with longer DFS (Log-rank test:
P =0.044; Fig. 3A) and longer OS (Log-rank test: P =0.044; Fig. 3B). (C, D) In ER positive carcinomas (n = 271), Kaplan Meier survival analysis
showed that there was no significant association between IGKC and DFS (Log-rank test: P = 0.088; Fig.3C), and OS had a borderline association with
IGKC (Log-rank test: P = 0.050; Fig.3D).
doi:10.1371/journal.pone.0044741.g003
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showed that high IGKC expression was associated with longer
DFS (Log-rank test: P = 0.044; Fig. 3A) and longer OS (Log-rank
test: P = 0.044; Fig. 3B). IGKC was not associated with DFS in
Kaplan Meier analysis in ER positive carcinomas (n = 271) (Log-
rank test: P = 0.088; Fig. 3C). OS showed a borderline significant
association with IGKC expression in Kaplan Meier analysis in ER
positive carcinomas (Log-rank test: P = 0.050; Fig. 3D).
When we separated the hormone receptor positive patients in
luminal A (n= 224) and luminal B (n= 55) we failed to detect any
significant impact of IGKC on DFS (Log-rank test: P = 0.591;
Fig. 4A) and OS (Log-rank test: P = 0.183; Fig. 4B) in luminal A
type cancer. In contrast, IGKC was significantly associated with
DFS (Log-rank test: P = 0.009; Fig. 4C) and showed a borderline
association with OS (Log-rank test: P = 0.057; Fig. 4D) in luminal
B carcinomas.
No significant correlations were found between IGKC expres-
sion and age at diagnosis (P = 0.824), pT stage (P= 0.063),
histological grade (P = 0.589), ER status (P = 0.131), PR status
(P = 0.138), HER-2 status (P = 0.871), and Ki-67 expression (P= 0.
306) (Table 5).
Discussion
The significance of the immune system is increasingly noticed in
breast cancer. Since different immune cell types may have
different functions, it is necessary to analyse the impact of
individual cell types on survival. Being aware of this problem,
several studies focusing on cellular immune response were done
Figure 4. In luminal A carcinomas (n=224), IGKC had no significant association with DFS (Log-rank test: P =0.591; Fig. 4A) and OS
(Log-rank test: P =0.183; Fig. 4B). (C, D) In luminal B carcinomas (n = 55), Kaplan-Meier curves illustrated that high IGKC expression had
significantly longer DFS than low IGKC expression (Log-rank test: P = 0.009; Fig. 4C). Moreover, OS also showed a borderline association with IGKC
(Log-rank test: P = 0.057; Fig. 4D).
doi:10.1371/journal.pone.0044741.g004
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and the protective impact of CD8+ T cell was confirmed [7–9].
The roles of B cells, however, remained elusive [10–13,15–18].
By using principal component analysis to visualize the
expression of several metagenes in breast cancer, our group
identified and characterized several metagenes associated with
biological motifs like B-cell, T-cell, proliferation and ER
metagenes, respectively. We showed that the B-cell metagene
was of pivotal importance as a prognostic factor in node-negative
breast cancer [10]. A confirmatory study performed by Bianchini
et al. [25] obtained comparable results. Since the B-cell metagene
includes 60 genes, it is labour-intensive and costly to analyse thus
precluding its use as a prognostic factor in the daily routine. To
solve this problem, we investigated IGKC as a representative
marker of the B-cell metagene. Its RNA expression was already
found to be associated with a good prediction of metastasis free
interval across several independent datasets [12]. Since prognostic
factors that are routinely used in breast cancer like ER, PR, HER-
2 or Ki-67 are measured using immunohistochemistry, analysing
IGKC at the protein level would be more convenient. By
immunostaining IGKC, our current study clearly highlighted its
favourable prognostic role in breast cancer. Kaplan-Meier
analysis, univariate and multivariate Cox analysis illustrated that
a stronger expression of IGKC was significantly associated with
improved breast cancer specific survival and DFS independent of
other prognostic factors in the entire cohort of node-negative
breast cancer patients. The prognostic impact of IGKC was
especially strong in ER negative and luminal B breast cancers.
Luminal A and luminal B are well defined intrinsic subtypes
separating hormone receptor positive patients into two subgroups
with distinct prognosis [26]. Even though gene array analysis was
initially used to define these subtypes, a simplified classification
using hormone receptor status, HER-2 status and histological
grade of differentiation as proliferation marker has been adopted
as a useful shorthand [21]. There was no association between
IGKC and prognosis in luminal A carcinomas. However, IGKC
had a strong prognostic impact in luminal B carcinomas. This is
consistent with studies reporting that in ER positive carcinomas,
the influence of the B-cell metagene was particularly strong in
highly proliferating breast cancer [10,25].
It is well described that over-expression of immune response
genes was more often identified in ER negative as compared with
ER positive breast cancer [27]. The study performed by Oh et al.
[28] explained this phenomenon further. These authors found that
highly proliferating breast cancer showed an association with an
enhanced immune response leading to better prognosis in both ER
positive and ER negative cancers. The proportions of highly
proliferative cancer cells in these two subtypes, however, were
different. According to their data, about 60% of ER negative
cancers were highly proliferating while in ER positive cancers the
proportion was only 17%. Accordingly, approximately 35% of ER
positive cancers were slowly growing as compared to only 8% ER
negative cancers. Interestingly, about 36% of ER negative cancers
had highly active immune response. The proportion of ER positive
cancers with high immune response was only 20%, therefore
supporting the notion that ER might have an inhibitory effect on
immune response. Low proliferative activity of ER positive breast
carcinomas might lead to an attenuated immune response and
hence to a comparatively poor prognosis. In the ER negative
cancers, however, a higher proportion of highly proliferative
cancer cells might result in a strong immune response as reflected
by a strong IGKC positive infiltrate, and thus these ER negative
cancers had a better survival. A similar association between
proliferation and immune response applies to highly proliferating
luminal B type carcinomas which show a strong influence of
IGKC expression.
A potential weakness of our study is the rather small sample size
of only 335 patients which might affect subgroup analysis due to
variable statistical power between subgroups of differing size with
varying numbers of events. A second shortcoming is the lack of an
independent validation cohort of node-negative patients not
treated in an adjuvant setting. A potential strength, though, is
that this population allows for assessing the pure prognostic effect
of a biomarker without potential predictive interaction.
In conclusion, our results demonstrate that IGKC is an
independent prognostic factor in untreated node-negative breast
cancer patients. The prognostic significance is most distinct in ER
negative as well as in luminal B breast cancer. IGKC is thus a
novel prognostic factor which lends itself to systematic testing in
formalin-fixed, paraffin-embedded tissue. Furthermore, it under-
scores the importance of a naturally occurring humoral immune
response against breast cancer.
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Table 5. Correlation of IGKC expression with
clinicopathological characteristics (n = 335).
Characteristics IGKC expression P*
Low (%) High (%)
No. of patients 175 (52.2) 160 (47.8)
Age at diagnosis
,50 years 43 (12.8) 41 (12.3) 0.824
$50 years 132 (39.4) 119 (35.5)
pT stage
#2 cm 124 (37.0) 98 (29.3) 0.063
.2 cm 51 (15.2) 62 (18.5)
Histological grade
G I and G II 143 (42.7) 127 (37.9) 0.589
G III 32 (9.5) 33 (9.9)
Estrogen receptor status
Negative 28 (8.4) 36 (10.7) 0.131
Positive 147 (43.9) 124 (37.0)
Progesterone receptor
status
Negative 42 (12.6) 50 (14.9) 0.138
Positive 133 (39.7) 110 (32.8)
HER-2 status
Negative 152 (45.3) 138 (41.2) 0.871
Positive 23 (6.9) 22 (6.6)
Ki-67 expression a
Low 120 (37.3) 115 (35.7) 0.306
High 50 (15.5) 37 (11.5)
*Correlation between variables was determined by Chi-Quare test.
HER-2 human epidermal growth factor receptor 2.
aThe total number of available cases for Ki-67 expression is 322.
doi:10.1371/journal.pone.0044741.t005
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